The VAI close-out at Mirfield is a clear positive for supply chain reliability, but the new Form 483 at Bachupally introduces fresh regulatory risk. Monitor for the company's response to the four observations and any subsequent USFDA re-inspection or warning letter. The mixed signal likely limits near-term upside.
Price Chart
Executive Summary
Dr. Reddy's filed two 6-Ks on August 14, 2026, disclosing USFDA inspection outcomes at two different facilities. The first filing reports that a GMP inspection at its Mirfield, UK API facility has been classified as 'Voluntary Action Indicated (VAI)' and officially closed — a positive resolution. The second filing reports that a GMP inspection at its Bachupally, Hyderabad formulations facility (FTO-3) resulted in a Form 483 with four observations, which the company will address. The net read is mixed: one facility receives a clean regulatory close-out, while another faces new compliance scrutiny.
Key Facts
- USFDA classified the inspection outcome at the Mirfield, UK API facility as 'Voluntary Action Indicated (VAI)' and officially closed the inspection under 21 CFR 20.64(d)(3).
- USFDA completed a GMP inspection at the Bachupally, Hyderabad formulations facility (FTO-3) from August 6 to August 14, 2026, and issued a Form 483 with four observations.
- The company stated it will address the four observations from the Form 483 within the stipulated timeline.
Financial Impact
No direct financial figures disclosed; the VAI close-out removes a regulatory overhang for the Mirfield facility, while the Form 483 at Bachupally introduces potential remediation costs and risk of future enforcement if observations are not adequately resolved.
Risk Factors
- Failure to adequately address the four Form 483 observations at Bachupally could lead to escalated USFDA action, including a warning letter or import alert.
- The VAI classification at Mirfield, while positive, does not guarantee future inspection outcomes and the facility remains subject to routine re-inspection.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (RDY) — Batch item 1 | 0001575872-26-000585 |
| Document: 0001575872-26-000585-index.html | 0001575872-26-000583 |
| Document: 0001575872-26-000585.txt | 0001575872-26-000585 |
| 6-K Filing (RDY) — Batch item 4 | 0001575872-26-000583 |
| Document: 0001575872-26-000583-index.html | 0001575872-26-000585 |
| Document: 0001575872-26-000583.txt | 0001575872-26-000585 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $11.91 $11.55 | ▼ −3.02% | ▼ −2.56% | $12.25 (+2.85%) |
Sep 10, 2026 22d ago | 6-K | $11.71 $11.90 | ▲ +1.62% | ▲ +0.77% | $12.25 (+4.61%) |
Sep 10, 2026 22d ago | 6-K | $11.71 $11.90 | ▲ +1.62% | ▲ +0.77% | $12.25 (+4.61%) |
Aug 26, 2026 5w ago | 6-K | $12.22 $12.16 | ▼ −0.49% | ▼ −1.15% | $12.25 (+0.25%) |
Aug 17, 2026 6w ago | 6-K | $12.11 $12.15 | ▲ +0.33% | ▲ +1.01% | $12.25 (+1.16%) |
Aug 13, 2026 7w ago | 6-K | $12.42 $12.27 | ▼ −1.21% | ▼ −1.01% | $12.25 (−1.37%) |
Aug 10, 2026 7w ago | 6-K | $12.15 $12.45 | ▲ +2.47% | ▲ +2.79% | $12.25 (+0.82%) |
Aug 3, 2026 8w ago | 6-K | $12.07 $12.10 | ▲ +0.25% | ▼ −1.55% | $12.25 (+1.49%) |
Jul 29, 2026 9w ago | 6-K | $11.76 $11.83 | ▲ +0.60% | ▼ −1.08% | $12.25 (+4.17%) |
Jul 23, 2026 10w ago | 6-K | $11.80 $11.79 | ▼ −0.08% | ▼ −0.19% | $12.25 (+3.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access